Bluetongue vaccines in Europe

The article reviews the history, present status and the future of BT vaccines in Europe. So far, an attenuated (modified live viruses, MLV) and inactivated virus vaccines against BT were developed and used in the field. Moreover, the virus-like particles (VLPs) produced from recombinant baculovirus, and live recombinant vaccinia or canarypox virus-vectored vaccines were tested in the laboratory. The main aims of BT vaccination strategy are: to prevent clinical disease, to reduce the spread of the BTV in the environment and to protect movement of susceptible animals between affected and free zones. Actually, all of the most recent European BT vaccination campaigns have used exclusively inactivated vaccines. The use of inactivated vaccines avoid risk associated with the use of live-attenuated vaccines, such as reversion to virulence, reassortment of genes with field strain, teratogenicity and insufficient attenuation leading to clinical disease. The mass vaccinations of all susceptible animals are the most efficient veterinary method to fight against BT and successful control of disease. The vaccination of livestock has had a major role in reducing BTV circulation and even in eradicating the virus from most areas of Europe.     

Bluetongue in the United Kingdom and northern Europe in 2007 and key issues for 2008

As predicted, bluetongue arrived in the UK in 2007. Here, John Gloster and colleagues investigate the meteorological parameters that allowed this incursion into the UK and discuss key issues related to the disease's possible re-establishment in 2008.     

Bluetongue serotype 8 vaccine coverage in northern and south-eastern England in 2008

A postal survey of all registered cattle and sheep farmers in East Anglia was carried out from July 2008 to determine bluetongue virus serotype 8 (BTV-8) vaccine uptake in the region. The vaccine was available to farmers in this region from May 2008. The survey was repeated in Cumbria and Northumberland at the beginning of 2009. In these regions, the vaccine was not available until September 1, 2008. Holding-level vaccine uptake was estimated to be 85 per cent (95 per cent confidence interval [CI] 83 to 87 per cent, n=1623) in East Anglia and 36 per cent (95 per cent CI 32 to 40 per cent, n=633) in northern England. A telephone follow-up of non-responders reduced these estimates to 79 and 29 per cent in East Anglia and northern England, respectively. In both regions, vaccine coverage was higher in sheep than in cattle, with 92 per cent of sheep in East Anglia having been vaccinated. The proportion of holdings that had applied the vaccine or were intending to apply the vaccine in 2009 in the northern region was 51 per cent (95 per cent CI 47 to 54 per cent, n=664), with a further 37 per cent undecided at the time of response.     

Bluetongue in Europe and the Mediterranean Basin: history of occurrence prior to 2006

Bluetongue virus (BTV) exists around the world in a broad band covering much of the Americas, Africa, southern Asia and northern Australia. Historically, it also occasionally occurred in the southern fringes of Europe. It is considered to be one of the most important diseases of domestic livestock. Recently BTV has extended its range northwards into areas of Europe never before affected and has persisted in many of these locations causing the greatest epizootic of bluetongue (BT), the disease caused by BTV, on record. Indeed, the most recent outbreaks of BT in Europe are further north than this virus has ever previously occurred anywhere in the world. The reasons for this dramatic change in BT epidemiology are complex but are linked to recent extensions in the distribution of its major vector, Culicoides imicola, to the involvement of novel Culicoides vector(s) and to on-going climate-change. This paper investigates these recent outbreaks in the European theatre, up to the beginning of 2006, highlights prospects for the future and sets the scene for the following papers in this special issue.     

Bluetongue in western Turkey

In October 1977 clinical bluetongue broke out in Aydin province, western Turkey and spread to adjacent provinces in the autumn months of 1978 and 1979. The outbreak was caused by a virus of serotype 4 and appeared to occur in a totally susceptible population. It was eventually controlled by widespread use of attenuated type-specific vaccine. Bluetongue virus was isolated from sheep on several occasions and also from a calf with congenital arthrogryposis and hydranencephaly. This latter finding is discussed in relation to Akabane virus, a recognised arbovirus teratogen thought to be present in the same area at the same time.     

The significance of interactions in practical sheep breeding in northern Europe

A brief summary of the sheep breed population in Eire, Scandinavia and United Kingdom is presented.The large number of breeds in the U.K. suggests that genotype environment interactions may well exist. Experimental evidence of both between breed and, more importantly, of within breed G × E interaction is summarised together with circumstantial evidence from the industry.The implications of such evidence are discussed in relation to the national improvement programme for each type of breed — hill, longwool and down breeds. The conclusion is that for hill breeds selected for reproduction traits the possibility of G × E interactions cannot be ignored, whereas for the slaughter sire breeds there appears to be less likelihood of serious effects. Some evidence suggests that artificial rearing, although an unnatural environment, can improve the rate of progress rather than decrease it.